Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9805410 | 0.89 | CYP11B1 (0.46) | NPC1RAB9ASMN1; SMN2L3MBTL1NFKB1 | |
| SCHEMBL9805625 | 0.89 | CYP11B1 (0.46) | NPC1RAB9ASMN1; SMN2L3MBTL1NFKB1 | |
| SCHEMBL397828 | 0.89 | CYP11B1 (0.48) | NPC1RAB9ASMN1; SMN2L3MBTL1NFKB1 | |
| SCHEMBL28682644 | 0.88 | CYP11B1 (0.56) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP11B1 | |
| SCHEMBL30747787 | 0.88 | CYP11B1 (0.56) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP11B1 | |
| SCHEMBL4417307 | 0.81 | HSD17B10 (0.54) | NPC1RAB9ASMN1; SMN2MAPK1CYP11B1 | |
| SCHEMBL4425760 | 0.81 | ALDH1A1 (0.54) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP11B1 | |
| SCHEMBL13527931 | 0.81 | CYP11B1 (0.48) | NPC1RAB9ASMN1; SMN2L3MBTL1NFKB1 | |
| SCHEMBL13568531 | 0.81 | ALDH5A1 (0.54) | NPC1RAB9ASMN1; SMN2CYP11B1ALDH1A1 | |
| SCHEMBL30578701 | 0.81 | KDM4E (0.54) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2492266-B1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2492266-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-0242716-B1 | LIQUID-CRYSTALLINE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-03-20 | — | — | EP | disclosed |
| US-4898455-A | Pyridine liquid crystalline compounds | HOFFMANN-LA ROCHE INC. (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0242716-A1 | Liquid-crystalline pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | EPOR, EGLN2, EGLN1 | NPC1 4523/4885RAB9A 4002/4885SMN1; SMN2 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.